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Individuals who survived EVD now face signifi cant health challenges. 2 Post-Ebola syndrome has been associated with uveitis, headache and other neurological symptoms, musculoskeletal pain, and insomnia, at least some of which are suspected to involve viral sequestration in body tissues and fl uids. 3 The medical issues of EVD survivors are often compounded by social stigmatisation due to fears of viral reactivation and potential transmission. Although pregnancy during acute EVD has been almost invariably associated with fetal loss, 4, 5 little is understood as to the antenatal courses and pregnancy outcomes in female EVD survivors who conceived after recovery.
We collated demographic and treatment history data on women who recovered from EVD and sought health care for pregnancy between October, 2014, and April, 2016, at designated referral facilities ( , respectively). In seven cases, the mothers' partners were also EVD survivors; six of the seven had apparently normal infants and one had a miscarriage.
Notably, of six pregnancies that occurred within 2 months of discharge from the Ebola treatment unit, three resulted in stillbirths (fi gure 1). One additional stillbirth occurred in a pregnancy conceived 6 months after recovery. In contrast, all 15 miscarriages occurred in women who became pregnant 4 months or longer after discharge (fi gure 1). The mean interval in months between recovery from acute EVD and conception was signifi cantly shorter in women who had stillbirths than in those who had miscarriages (mean 2·5 months [SD 2·4] vs 9·9 months [3·0] ; p=0·0011).
The overall miscarriage rate in clinically identifi ed pregnancies for this cohort of Ebola survivors (15/68; 22·1%) was slightly higher than the ranges expected for healthy women in developed countries (10-15%) 6 and women in west Africa (11-13%), 7 although published data on miscarriages are sparse. Taken together, the rate of adverse pregnancy outcomes in the present cohort (19/68; 27·9%) suggests the possibility that EVD engendered reproductive health risks after clinical disease resolved, especially when pregnancy occurred within 2 months of recovery. Prospective evaluation of additional pregnancy outcomes in EVD survivors compared to age-matched controls from west Africa will be helpful to further quantify the relative risks of adverse pregnancy outcomes.
We disclose a number of caveats to the interpretation of these fi ndings. Liberia-specifi c miscarriage rates among uninfected women before, during, or after the acute epidemic were not available. EVD survivors who noted or suspected problems with their pregnancy may have been more likely to seek medical attention than those who did not. Indeed, the vast diff erence in miscarriage frequencies between Margibi (9/16; 56·3%) and Montserrado (6/52; 11·5%) counties suggests a possible case-fi nding artifact; we are unaware of a biologically plausible explanation. Conversely, it is conceivable that our fi ndings underestimate the number of stillbirths and miscarriages among EVD survivors; for example, under-reporting may have occurred due to fear of stigmatisation or because of disrupted health services in the aftermath of the Ebola outbreak.
It has been postulated that Ebola virus persistence in immune-privileged sites such as brain and retina may pose risks to the developing fetus of the gravid EVD survivor. 8 Male survivors have been shown to shed Ebola virus RNA in semen for at least 18 months after onset of EVD. 9 There has been one report of Ebola virus relapse in the central nervous system of a 39-yearold female EVD survivor. 10 Evidence of Ebola virus persistence in other female survivors of childbearing age would heighten the concerns raised here. If confi rmed, potential mechanistic questions include whether the reduced immune response during pregnancy and the immunological functions of the placenta, which allow fetus and mother to co-exist, may increase risk of reactivation, and whether genetic risk factors play a role. 
